TG THERAPEUTICS, INC. 8-K

What Happened
TG Therapeutics, Inc. (TGTX) announced results of operations for the three months ended March 31, 2026 via a press release dated May 6, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K (Item 2.02), making its quarterly results public on that date.

Key Details

• Press release date and filing: May 6, 2026 (filed on Form 8-K, Item 2.02).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• The press release is furnished as Exhibit 99.1 to the Form 8-K.
• The Form 8-K also includes the Inline XBRL cover page (Exhibit 104).

Why It Matters
The 8-K indicates TG Therapeutics has publicly released its quarterly results (earnings/revenue and other operational metrics) for Q1 2026; investors should read the press release and accompanying filings to see the company’s reported revenue, net income/loss, cash position, and any commentary on business operations or outlook. Quarterly results can affect share price and investor sentiment, so review the detailed press release (Exhibit 99.1) and subsequent SEC filings for specific figures and management discussion.